Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Arthritis Research & Therapy

Francesca Bobbio-Pallavicini²  Claudia Alpini¹  Roberto Caporali²  Stefano Avalle¹  Serena Bugatti²  Carlomaurizio Montecucco² 

[1] Clinical Chemistry Laboratories University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy

[2] Department of Rheumatology University of Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy

关键词: rheumatoid factor;    infliximab;    antinuclear antibodies;    anti-dsDNA antibodies;    anti-citrullinated peptide antibodies;   

Others  :  1101262
DOI  :  10.1186/ar1173

 received in 2004-01-22, accepted in 2004-03-09,  发布年份 2004

【 摘 要 】

The aim of the present study was to investigate the effect of long-term infliximab treatment on various autoantibodies in patients with rheumatoid arthritis. Serum samples from 30 consecutive patients, who were prospectively followed during infliximab and methotrexate therapy for refractory rheumatoid arthritis, were tested at baseline and after 30, 54 and 78 weeks. At these points, median values of the Disease Activity Score were 6.38 (interquartile range 5.30–6.75), 3.69 (2.67–4.62), 2.9 (2.39–4.65) and 3.71 (2.62–5.06), respectively. Various autoantibodies were assessed by standard indirect immunofluorescence and/or ELISA. Initially, 50% of patients were positive for antinuclear antibodies, and this figure increased to 80% after 78 weeks (P = 0.029). A less marked, similar increase was found for IgG and IgM anticardiolipin antibody titre, whereas the frequency of anti-double-stranded DNA antibodies (by ELISA) exhibited a transient rise (up to 16.7%) at 54 weeks and dropped to 0% at 78 weeks. Antibodies to proteinase-3 and myeloperoxidase were not detected. The proportion of patients who were positive for rheumatoid factor (RF) was similar at baseline and at 78 weeks (87% and 80%, respectively). However, the median RF titre exhibited a progressive reduction from 128 IU/ml (interquartile range 47–290 IU/ml) to 53 IU/ml (18–106 IU/ml). Anti-cyclic citrullinated peptide (CCP) antibodies were found in 83% of patients before therapy; anti-CCP antibody titre significantly decreased at 30 weeks but returned to baseline thereafter. In conclusion, the presence of anti-double-stranded DNA antibodies is a transient phenomenon, despite a stable increase in antinuclear and anticardiolipin antibodies. Also, the evolution of RF titres and that of anti-CCP antibody titres differed during long-term infliximab therapy.

【 授权许可】

   
2004 Bobbio-Pallavicini et al.; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden Jr, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy Study Group. N Engl J Med 2000, 343:1594-1602.
• [2]Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
• [3]Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harrimann G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
• [4]Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkefeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, Mc Donnell ND, Weinblatt ME: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
• [5]Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
• [6]Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN: Assessment of antibodies to double-stranded DNA induced in rheumathoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2390.
• [7]De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003, 48:1015-1023.
• [8]Antivalle M, Marazza MG, Randisi G, Sarzi-Puttini P, Dell'Acqua D, Carrabba M: Long-term treatment of rheumatoid arthritis with infliximab: efficacy, side effects and autoantibodies induction [abstract]. Arthritis Rheum 2002, 46:s534.
• [9]Gershov D, Kim S, Brot N, Elkon KB: C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000, 192:1353-1364.
• [10]Pisetsky DS: Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000, 43:2381-2382.
• [11]Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR: Role of apoptosis in autoimmunity. Apoptosis 2000, 5:443-449.
• [12]Schultz DR, Harrington WJ jr: Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum 2003, 32:345-369.
• [13]Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not Etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
• [14]Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR: Defective mucosal T cell death is sustainably reverted by infliximab in a capsase dependent pathway in Crohn's disease. Gut 2004, 53:70-77.
• [15]Vermiere S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P: Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003, 125:32-39.
• [16]Garcia-Planella E, Domenech E, Esteve-Comas M, Bernal I, Cabre E, Boix J, Gassull MA: Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003, 15:351-354.
• [17]Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL: The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43:1831-1835.
• [18]Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B: Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five years radiographic damage. Ann Rheum Dis 2003, 62:120-126.
• [19]Bas S, Genevay S, Meyer O, Gabay C: Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 2003, 42:677-680.
• [20]Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357-365.
• [21]Olsen NJ, Callahan LF, Pincus T: In vitro rheumatoid factor synthesis in patients taking second-line drugs for rheumatoid arthritis. Independent associations with disease activity. Arthritis Rheum 1988, 31:1090-1096.
• [22]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
• [23]Prevoo ML, van't Hof MA, Kuper HH, van Leeuween MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
• [24]Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
• [25]Brito J, Biamonti G, Caporali R, Montecucco C: Autoantibodies to human nuclear lamin B2 protein. Epitope specificity in different autoimmune diseases. J Immunol 1994, 153:2268-2277.
• [26]von Muhlen CA, Tan EM: Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995, 24:323-258.
• [27]Bootsma H, Spronk PE, Hummel EJ, de Boer G, ter Borg EJ, Limburg PC, Kallenberg CG: Anti-double stranded DNA antibodies in systemic lupus erythematosus: detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996, 25:352-359.
• [28]Cairns AP, Duncan MK, Hinder AE, Taggart AJ: New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002, 61:1031-1032.
• [29]Shakoor N, Michalska M, Harris CA, Block JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002, 359:579-580.
• [30]Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O: Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003, 22:56-61.
• [31]Favalli EG, Sinigaglia L, Varenna M, Arnoldi C: Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002, 11:753-755.
• [32]Ali Y, Shah S: Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002, 137:625-626.
• [33]Carlson E, Rothfield N: Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 2003, 48:1165-1166.
• [34]Lepore L, Marchetti F, Facchini S, Leone V, Ventura A: Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003, 21:276-277.
• [35]Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM: Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002, 360:646.
• [36]Ferraccioli G, Mecchia F, Di Poi E, Fabris M: Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002, 61:358-361.
• [37]Jonsdottir T, Harju A, van Vollenhoven A, Klareskog L, van Vollenhoven R: Treatment with TNF-antagonist is associated with an increasing frequency of anticardiolipin antibodies (ACLA)-ACLA positivity predicts worse clinical outcomes [abstract]. Arthritis Rheum 2002, 46:s573.
• [38]Belfiore N, Rossi S, Bobbio Pallavicini F, Epis O, Caporali R, Montecucco C: Anti-Ro(SS-A) 52 kDa and 60 kDa specificities in undifferentiated connective tissue disease. Joint Bone Spine 2000, 67:183-187.
• [39]Smeets TJ, Kraan MC, van Loon ME, Tak PP: Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155-2162.
• [40]Reparon-Schuijt CC, van Esch WJ, van Kooten C, Levarht EW, Breedveld FC, Verweij CL: Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum 1998, 41:2211-2220.